Log in

NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News

$38.18
-1.32 (-3.34 %)
(As of 04/8/2020 07:12 AM ET)
Add
Compare
Today's Range
$37.55
Now: $38.18
$40.78
50-Day Range
$31.52
MA: $41.83
$53.68
52-Week Range
$27.77
Now: $38.18
$68.85
Volume651,734 shs
Average Volume718,664 shs
Market Capitalization$2.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Read More
Agios Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share

Profitability

Net Income$-411,470,000.00
Net Margins-348.96%

Miscellaneous

Employees482
Market Cap$2.62 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.


Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGIO stock has decreased by 6.6% and is now trading at $38.18. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Agios Pharmaceuticals.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) posted its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to analyst estimates of $33.72 million. Agios Pharmaceuticals had a negative return on equity of 73.42% and a negative net margin of 348.96%. The firm's revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.58) EPS. View Agios Pharmaceuticals' earnings history.

What price target have analysts set for AGIO?

12 Wall Street analysts have issued 1 year target prices for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $79.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $63.10 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

News headlines about AGIO stock have trended very negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAgios Pharmaceuticals.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), bluebird bio (BLUE), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), Micron Technology (MU) and AbbVie (ABBV).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $38.18.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.62 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe. View additional information about Agios Pharmaceuticals.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com/.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Hold Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel